| 1. |
- Alm, Per A., et al.
(författare)
-
Hemispheric Lateralization of Motor Thresholds in Relation to Stuttering
- 2013
-
Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 8:10, s. e76824-
-
Tidskriftsartikel (refereegranskat)abstract
- Stuttering is a complex speech disorder. Previous studies indicate a tendency towards elevated motor threshold for the left hemisphere, as measured using transcranial magnetic stimulation (TMS). This may reflect a monohemispheric motor system impairment. The purpose of the study was to investigate the relative side-to-side difference (asymmetry) and the absolute levels of motor threshold for the hand area, using TMS in adults who stutter (n = 15) and in controls (n = 15). In accordance with the hypothesis, the groups differed significantly regarding the relative side-to-side difference of finger motor threshold (p = 0.0026), with the stuttering group showing higher motor threshold of the left hemisphere in relation to the right. Also the absolute level of the finger motor threshold for the left hemisphere differed between the groups (p = 0.049). The obtained results, together with previous investigations, provide support for the hypothesis that stuttering tends to be related to left hemisphere motor impairment, and possibly to a dysfunctional state of bilateral speech motor control.
|
|
| 2. |
|
|
| 3. |
- Almgren, Jonas, et al.
(författare)
-
SICStus Prolog library manual, version 2.1 #8
- 1993. - 1
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This Manual corresponds to SICStus Prolog release 2.1. #8 The Prolog library comprises a number of packages which are thought to be useful in a number of applications. Note that the predicates in the Prolog library are built-in predicates. One has to explicity load each package to get access to its predicates. To load a library package Package, you will normally enter a query. I ?- use_module(library(Package)). Library packages may be compiled and consulted as well as loaded.
|
|
| 4. |
- Andersson, Maria, et al.
(författare)
-
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
- 2023
-
Ingår i: Journal of Hematology. - : Elmer Press, Inc.. - 1927-1212 .- 1927-1220. ; 12:4, s. 170-175
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Patients with chronic lymphocytic leukemia (CLL) are vulnerable to coronavirus disease 2019 (COVID-19) and are at risk of inferior response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, especially if treated with the first-generation Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib. We aimed to evaluate the impact of the third-generation BTKi, zanubrutinib, on systemic and mucosal response to SARS-CoV-2 vaccination.Methods: Nine patients with CLL with ongoing zanubrutinib therapy were included and donated blood and saliva during SARS-CoV-2 vaccination, before vaccine doses 3 and 5 and 2 - 3 weeks after doses 3, 4, and 5. Ibrutinib-treated control patients (n = 7) and healthy aged-matched controls (n = 7) gave blood 2 - 3 weeks after vaccine dose 5. We quantified reactivity and neutralization capacity of SARS-CoV-2-specific IgG and IgA antibodies (Abs) in both serum and saliva, and reactivity of T cells activated with viral peptides.Results: Both zanubrutinib- and ibrutinib-treated patients had significantly, up to 1,000-fold, lower total spike-specific Ab levels after dose 5 compared to healthy controls (P < 0.01). Spike-IgG levels in serum from zanubrutinib-treated patients correlated well to neutralization capacity (r = 0.68; P < 0.0001) and were thus functional. Mucosal immunity (specific IgA in serum and saliva) was practically absent in zanubrutinib-treated patients even after five vaccine doses, whereas healthy controls had significantly higher levels (tested in serum after vaccine dose 5) (P < 0.05). In contrast, T-cell reactivity against SARS-CoV-2 peptides was equally high in zanubrutinib- and ibrutinib-treated patients as in healthy control donors.Conclusions: In our small cohort of zanubrutinib-treated CLL patients, we conclude that up to five doses of SARS-CoV-2 vaccination induced no detectable IgA mucosal immunity, which likely will impair the primary barrier defence against the infection. Systemic IgG responses were also impaired, whereas T-cell responses were normal. Further and larger studies are needed to evaluate the impact of these findings on disease protection.
|
|
| 5. |
- Bergström, Maria, et al.
(författare)
-
Ne bis in idem : – a continuing judicial dialogue
- 2022
-
Ingår i: The Practice of Judicial Interactions in the Field of Fundamental Rights. - : Edward Elgar Publishing. - 9781800371217 - 978 1 80037 122 4 ; , s. 295-317
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- The principle of ne bis in idem is explicitly included in numerous international, regional and bilateral instruments. The interrelationship and parallel application of these legal instruments by a variety of courts may entail a number of legal challenges but also opportunities. In particular, introducing the EU Charter had an enormous impact on fundamental rights protection and the outcome of the well-known Åkerberg Fransson saga that eventually prohibited double proceedings and punishments with respect to value added tax. At the same time, judicial interaction between national and European courts played a significant role throughout this saga. While using the Åkerberg Fransson saga as a reference point and illustrative example, this chapter aims at analysing the judicial interaction involved in light of more recent developments before the European Court of Justice, CJEU, and the European Court of Human Rights, ECtHR. As a result of this analysis, we conclude that courts are instrumental not only in the settlement of individual disputes, but also in changing the legal system.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Carlsson, Jörgen, et al.
(författare)
-
Planning for intracavitary anti-EGFR radionuclide therapy of gliomas : Literature review and data on EGFR expression
- 2006
-
Ingår i: Journal of Neuro-Oncology. - : Springer Science and Business Media LLC. - 0167-594X .- 1573-7373. ; 77:1, s. 33-45
-
Tidskriftsartikel (refereegranskat)abstract
- Targeting with radionuclide labelled substances that bind specifically to the epidermal growth factor receptor, EGFR, is considered for intracavitary therapy of EGFR-positive glioblastoma multiforme, GBM. Relevant literature is reviewed and examples of EGFR expression in GBM are given. The therapeutical efforts made so far using intracavitary anti-tenascin radionuclide therapy of GBM have given limited effects, probably due to low radiation doses to the migrating glioma cells in the brain. Low radiation doses might be due to limited penetration of the targeting agents or heterogeneity in the expression of the target structure. In this article we focus on the possibilities to target EGFR on the tumour cells instead of an extracellular matrix component. There seems to be a lack of knowledge on the degree of intratumoral variation of EGFR expression in GBM, although the expression seemed rather homogeneous over large areas in most of the examples (n=16) presented from our laboratory. The observed homogeneity was surprising considering the genomic instability and heterogeneity that generally characterises highly malignant tumours. However, overexpression of EGFR is, at least in primary GBMs, one of the steps in the development of malignancy, and tumour cells that lose or downregulate EGFR will probably be outgrown in an expanding tumour cell population. Thus, loss of EGFR expression might not be the critical factor for successful intracavitary radionuclide therapy. Instead, it is likely that the penetration properties of the targeting agents are critical, and detailed studies on this are urgent.
|
|
| 10. |
|
|
